https://www.pharmaradar360.com/article/bc0a96684d6a00a5PharmaRadar360en2026-04-03T01:00:00.000ZMenicon Renames Its Sales Subsidiaries in Malaysia and Indonesia – Promoting Brand Integration and Business Expansion in Southeast Asia –https://www.pharmaradar360.com/article/f0a809b2df1cd379PharmaRadar360en2026-04-03T00:00:00.000ZBristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026https://www.pharmaradar360.com/article/721ba76c6198b4a6PharmaRadar360en2026-04-03T00:00:00.000ZBazar el Regalo raises €13,644 for personalised medicine and paediatric cancer researchhttps://www.pharmaradar360.com/article/9e969e73c1339af9PharmaRadar360en2026-04-02T16:00:00.000ZLa FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o aguahttps://www.pharmaradar360.com/article/4387a8639a1018acPharmaRadar360en2026-04-02T12:30:00.000ZAbeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New Yorkhttps://www.pharmaradar360.com/article/4ee85ecdd20d96d3PharmaRadar360en2026-04-02T12:00:00.000ZEmergent BioSolutions Participates in Upcoming International Preparedness Conferenceshttps://www.pharmaradar360.com/article/904dabca01527d35PharmaRadar360en2026-04-02T10:00:00.000ZChemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancerhttps://www.pharmaradar360.com/article/0676c51a13496ff4PharmaRadar360en2026-04-02T10:00:00.000ZReply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial," and "Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer"https://www.pharmaradar360.com/article/e4c6eef3c3da33d0PharmaRadar360en2026-04-02T10:00:00.000ZKey Methodological Considerations in the Interpretation of the CONKO-007 Trialhttps://www.pharmaradar360.com/article/950421846a24d0cePharmaRadar360en2026-04-02T10:00:00.000ZChemoradiotherapy in Pancreatic Cancer: Toward Precision Oncologyhttps://www.pharmaradar360.com/article/aaa1659b71b8c860PharmaRadar360en2026-04-02T10:00:00.000ZGonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trialhttps://www.pharmaradar360.com/article/0200ca85867ba791PharmaRadar360en2026-04-02T10:00:00.000ZBreaking new ground with antibody-drug conjugates in myelomahttps://www.pharmaradar360.com/article/261e01272bcbad88PharmaRadar360en2026-04-02T10:00:00.000ZAccess to CAR T-cell therapy across diverse global marketshttps://www.pharmaradar360.com/article/d36dbe98ec8d7314PharmaRadar360en2026-04-02T10:00:00.000ZFan X, Xi Q. Flow cytometry-based evaluation of TRBC1/TRBC2 facilitates identification of indolent T-lymphoblastic proliferations. Blood. 2026;147(6):702https://www.pharmaradar360.com/article/dfe172ba5e8a391bPharmaRadar360en2026-04-02T10:00:00.000ZArora J, Ayyappan S, Yin C, et al. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC. Blood. 2024;143(18):1816-1824https://www.pharmaradar360.com/article/0183d58f5013d66cPharmaRadar360en2026-04-02T10:00:00.000ZMetamizole-induced agranulocytosis resulting in ecthyma gangrenosum after an AI chatbot queryhttps://www.pharmaradar360.com/article/81c1b04b5cbfa7adPharmaRadar360en2026-04-02T08:24:42.000ZThe tumor microbiota: a new frontier in cancer biologyhttps://www.pharmaradar360.com/article/025cba2fbc2e1564PharmaRadar360en2026-04-02T07:30:00.000ZAnnounced: the fifteen shortlisted images in the IDIBAPS 2026 Scientific Photography Competition